A new trading day began on Monday, with Novo Nordisk ADR (NYSE: NVO) stock price up 1.29% from the previous day of trading, before settling in for the closing price of $48.19. NVO’s price has ranged from $46.90 to $139.74 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 21.74%. Meanwhile, its annual earnings per share averaged 24.45%. With a float of $3.37 billion, this company’s outstanding shares have now reached $3.37 billion.
The extent of productivity of a business whose workforce counts for 76302 workers is very important to gauge. In terms of profitability, gross margin is 84.33%, operating margin of 44.53%, and the pretax margin is 43.65%.
Novo Nordisk ADR (NVO) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Drug Manufacturers – General Industry. The insider ownership of Novo Nordisk ADR is 0.00%, while institutional ownership is 9.66%. The most recent insider transaction that took place on May 30 ’25, was worth 1,972,859.
Novo Nordisk ADR (NVO) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of 5.99 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 24.45% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 14.97% during the next five years compared to 21.74% growth over the previous five years of trading.
Novo Nordisk ADR (NYSE: NVO) Trading Performance Indicators
Here are Novo Nordisk ADR’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 0.56. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.77. Likewise, its price to free cash flow for the trailing twelve months is 11.50.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 3.37, a number that is poised to hit 0.92 in the next quarter and is forecasted to reach 4.35 in one year’s time.
Technical Analysis of Novo Nordisk ADR (NVO)
The latest stats from [Novo Nordisk ADR, NVO] show that its last 5-days average volume of 56.49 million was superior to 10.8 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 4.51%.
During the past 100 days, Novo Nordisk ADR’s (NVO) raw stochastic average was set at 5.35%, which indicates a significant decrease from 7.67% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.57 in the past 14 days, which was lower than the 1.83 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $68.73, while its 200-day Moving Average is $82.36.
